Cellectis S.A. Investor Relations Material

Cellectis is a clinical stage biotechnological company, developing immuno-oncology products based on gene-edited T-cells. According to Cellectis, it is one of the very few companies capable of generating next generation T-cell product candidates in an entirely novel approach. By combining the full functionality of T-cells with the specificity provided by artificial antigen receptors (chimeric antigen receptors), their program aims at achieving superior antiviral, anti-tumor and anti-inflammatory potential

Latest company events